Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 10
Semaglutide for Young People
An English expert consensus follows STEP TEENS, where semaglutide reduced adolescent BMI but adverse events and policy limits still matter.
Retatrutide import rules in Denmark
Denmark permits some personal medicine imports, but grey-market retatrutide lacks a verified lawful-sale route under the 2026 rules.
Semaglutide status in Denmark
Authorised semaglutide products remain prescription medicines in Denmark. The 2026 change concerns private imports, not deregulation.
TB-500 import rules in Denmark
Denmark's 2026 private-import rules are conditional, and TB-500 has no routine authorised Danish pack. Here is the source-bounded answer.
TB-500 cost in Denmark
No official Danish TB-500 pharmacy price or routine reimbursement could be verified because no authorised pack was identified.
TB-500 status in Denmark
Denmark has no verified authorised TB-500 medicine route. The 2026 import reform did not create an approval or pharmacy product.
Tirzepatide import rules in Denmark
Denmark permits some personal tirzepatide imports, but only when the exact medicine was lawfully sold and is supported by proper records.
Digital Support With GLP-1 Drugs
A retrospective program study linked app use with higher odds of weight-loss milestones, but self-selection prevents a causal conclusion.
Semaglutide Safety by Frailty in SELECT
A SELECT post hoc analysis found no detectable difference in cardiovascular benefit across baseline frailty categories, with important safety limits.
GLP-1 Injection-Site Amyloidosis Case
A 2026 case report describes a rare abdominal amyloid deposit after use of three injectable incretin medicines, with liraglutide detected at low levels.
GLP-1 versus SGLT2: a confounded cohort
A matched records study favored GLP-1 drugs in MASLD with heart failure, but early separation makes treatment channeling likely.
Semaglutide and cardiovascular death
Seven randomized trials suggest a 17% lower relative hazard of cardiovascular death with semaglutide versus placebo.